Home
Search

Press Releases

Get the latest on BIO's announcements, positions and views on everything from healthcare to biofuels. 

Featured Press Releases
BIO Statement Regarding Nomination of Robert F…
BIO President & CEO John F. Crowley released the following statement:“A healthy and prosperous society is vitally important to the American people and to the world. The public health, economic security and our national security are best served…
Learn more
BIO Released the Following Statement After…
“The Biotechnology Innovation Organization (BIO) applauds today's announcement from the USDA's Animal and Plant Health Inspection Service (APHIS) expanding the scope of biotechnology exemptions for modified plants under 7 CFR part 340. This…
Learn more
BIO Statement on Lawsuit Over 340B Rebates
BIO strongly supports a manufacturer’s ability to use a 340B rebate as an appropriate option to make 340B pricing available to covered entities."Manufacturers should have the choice to effectuate 340B pricing in the manner they deem most efficient…
Learn more
All Press Releases
  • Show All
Search
Results
Event Tags
Dr. Michelle McMurry-Heath Statement on Recent Gun Violence
May 27, 2022
Dr. Michelle McMurry-Heath, President and CEO of the Biotechnology Innovation Organization (BIO), released the following statement responding to recent incidences of gun violence across the country: "I couldn’t sleep last night. It has been an…
Olympian and Grand Slam Champion Venus Williams and Sportscasting Legend Erin Andrews Share Their Patient Perspectives with Biotech Community
May 19, 2022
Seven-time Grand Slam singles champion, four-time Olympic gold medalist and entrepreneur Venus Williams will discuss her groundbreaking career, business success, and health journey in a conversation with Emmy-nominated sports reporter Erin Andrews…
BIO Response to Second Global COVID-19 Summit
May 12, 2022
The White House today hosted world leaders and key public and private sector partners at the second Global COVID-19 Summit, a virtual event. Following the conversation, Dr. Michelle McMurry-Heath, President and CEO of the…
BIO Statement on New PDUFA Package
May 4, 2022
The House Energy & Commerce Committee today unveiled a new package for the Prescription Drug User Fee Act (PDUFA). After the release, BIO’s Chief Science Officer, Cartier Esham, made the following remarks:  "For more than thirty years, the…
BIO Statement on USTR Special 301 Report
April 29, 2022
 USTR this week released its 2022 Special 301 Report. BIO, after reviewing the report, released the following statement: We welcome USTR’s efforts to address IP-related concerns for U.S.-based biotech enterprises in China, especially…
New Ways & Means health package a "critical building block for future biotech innovation"
April 19, 2022
In an effort to secure medical supply chains and invest in the cures and treatment of the future, members of the House Ways and Means committee this week reintroduced major legislation that "ensures a healthier future for all Americans." BIO…
CMS Decision is an Enormous Setback for Alzheimer's Patients and a Dangerous Infringement on FDA's Scientific Autonomy
April 7, 2022
Dr. Michelle McMurry-Heath, President and CEO of the Biotechnology Innovation Organization (BIO), released the following statement in response to the Centers for Medicare and Medicaid Services’ (CMS’s) National Coverage Determination (NCD) to…
New Season of Biotech Podcast Builds Trust in Science
March 22, 2022
Washington, D.C.– The Biotechnology Innovation Organization (BIO) today premieres its new season of the I AM BIO podcast, which tells powerful stories across the biotechnology industry and how it heals, fuels, and feeds our world. The season…
BIO Statement on Reports of a Proposed Deal on COVID-19 Vaccine IP Rights Waiver
March 15, 2022
John Murphy, Chief Policy Officer at the Biotechnology Innovation Organization (BIO), released the following statement regarding reports of a proposed deal on a Covid-19 vaccine intellectual property rights waiver: “While we have seen the reported…
BIO Statement on Russia's Decision To Legalize Patent Theft
March 11, 2022
“Retaliation of this kind will only serve to isolate Russian science and technology from the international mainstream. At the end of the day those who will be most hurt by this decision will not be innovative global companies, but Russian patients,…
gooddaybio-cover-final
Daily News You Can’t Afford to Miss

Read it in under 3 minutes!

The Good Day BIO newsletter is the only daily newsletter at the intersection of biotech, politics, and policy. 

Sign Up Today